Not all genomic tests are the same.
Genomic testing proves that there’s more to the story than clinical factors can tell us. It helps us more comprehensively understand a tumor’s behavior, including why it’s growing, how aggressive it is and what we should expect it to do in the future.
MammaPrint is a type of test that shows the likelihood of your cancer returning, while BluePrint classifies the cancer as a specific subtype.
How does genomic testing affect your treatment plan?
By gaining a deeper, molecular view into the cancer, your doctors will have a better idea of how your body is going to respond to different treatments. They’ll be able to rule out therapies that most likely won’t be effective and determine which ones have a good chance of working well.
The MammaPrint test is most helpful for deciding whether or not to use chemotherapy. A BluePrint test, on the other hand, can help your doctors choose among a variety therapies based on the cancer’s subtype.
Luminal A-Type – 73%
These cancers tend to grow slowly, are not likely to recur and usually have good outcomes. They are commonly treated with hormonal therapy since they are estrogen-receptor and/or progesterone-receptor positive. Luminal A-Type = 73% of all breast cancer cases.
Basal-Type – 13%
Also called Triple-Negative, these cancers are the most aggressive of the four types and associated with the lowest survival rates. They don’t respond well to hormonal therapies, but they can be successfully treated with pre-surgery chemotherapy. Basal-Type = 13% of all breast cancer cases.
Luminal B-Type – 10%
These cancers generally grow faster, are more likely to recur and have lower survival rates than Luminal A cancers. They don’t respond as well to hormonal treatment as Luminal A cancers, but often benefit from pre-surgery chemotherapy. Luminal B-Type = 10% of all breast cancer cases.
HER2-Type – 5%
These cancers tend to grow faster than luminal cancers and are more resistant to hormonal treatments, but can often be successfully treated with targeted therapies aimed at the HER2 protein. Basal-Type = 5% of all breast cancer cases.